NUVL Stock Overview
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Nuvalent, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$66.07 |
52 Week High | US$89.39 |
52 Week Low | US$33.03 |
Beta | 1.3 |
1 Month Change | -12.77% |
3 Month Change | -13.41% |
1 Year Change | 92.34% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 252.37% |
Recent News & Updates
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Apr 22Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Feb 26Recent updates
Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Apr 22Nuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024
Feb 26Is Nuvalent, Inc. (NASDAQ:NUVL) Trading At A 36% Discount?
Jan 07Companies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In Growth
Sep 23Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Jun 10We're Interested To See How Nuvalent (NASDAQ:NUVL) Uses Its Cash Hoard To Grow
Feb 24Here's Why We're Not Too Worried About Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
Sep 13Nuvalent GAAP EPS of -$0.38 beats by $0.03
Aug 10Here's Why We're Not At All Concerned With Nuvalent's (NASDAQ:NUVL) Cash Burn Situation
May 28We're Hopeful That Nuvalent (NASDAQ:NUVL) Will Use Its Cash Wisely
Oct 29Shareholder Returns
NUVL | US Biotechs | US Market | |
---|---|---|---|
7D | 4.8% | 1.0% | 1.2% |
1Y | 92.3% | 0.7% | 24.9% |
Price Volatility
NUVL volatility | |
---|---|
NUVL Average Weekly Movement | 5.9% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: NUVL's share price has been volatile over the past 3 months.
Volatility Over Time: NUVL's weekly volatility (6%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2017 | 92 | Jim Porter | www.nuvalent.com |
Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Nuvalent, Inc. Fundamentals Summary
NUVL fundamental statistics | |
---|---|
Market cap | US$4.23b |
Earnings (TTM) | -US$126.22m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-33.5x
P/E RatioIs NUVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NUVL income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$126.22m |
Earnings | -US$126.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.97 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NUVL perform over the long term?
See historical performance and comparison